Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2013

01-02-2012 | Editorial

Steps solidifying a role for SEPT9 in breast cancer suggest that greater strides are needed

Authors: Laura Stanbery, Elizabeth M Petty

Published in: Breast Cancer Research | Issue 1/2013

Login to get access

Abstract

Septins comprise a conserved family of GTPase proteins. Of these, human SEPT9 has been widely implicated in cancers of epithelial origin, including breast cancer, as well as leukemia. In a previous issue of Breast Cancer Research, Connolly and colleagues present compelling data further supporting a role for SEPT9 isoforms in early breast cancer development as well as evidence suggesting that cellular localization patterns of SEPT9 isoforms may contribute to oncogenesis.
Literature
1.
Connolly D, Yang Z, Castaldi M, Simmons N, Oktay MH, Coniglio S, Fazzari MJ, Verdier-Pinard P, Montagna C: Septin 9 isoform expression, localization and epigenetic changes during human and mouse breast cancer progression. Breast Cancer Res. 2011, 13: R76-10.1186/bcr2924.CrossRefPubMedPubMedCentral
2.
Hartwell LH: Genetic control of the cell division cycle in yeast. IV. Genes controlling bud emergence and cytokinesis. Exp Cell Res. 1971, 69: 265-276. 10.1016/0014-4827(71)90223-0.CrossRefPubMed
3.
Russell SEH, Hall PA: Septin genomics: a road less travelled. Biol Chem. 2011, 392: 763-767. 10.1515/BC.2011.079.CrossRefPubMed
4.
Peterson EA, Petty EM: Conquering the complex world of human septins: implications for health and disease. Clin Genet. 2010, 77: 511-524. 10.1111/j.1399-0004.2010.01392.x.CrossRefPubMedPubMedCentral
5.
Connolly D, Abdesselam I, Verdier-Pinard P, Montagna C: Septin roles in tumorigenesis. Biol Chem. 2011, 392: 725-738. 10.1515/BC.2011.073.CrossRefPubMed
6.
Roeseler S, Sandrock K, Bartsch I, Zieger B: Septins, a novel group of GTP-binding proteins: relevance in hemostasis, neuropathology and oncogenesis. Klin Padiatr. 2009, 221: 150-155. 10.1055/s-0029-1220706.CrossRefPubMed
7.
Osaka M, Rowley JD, Zeleznik-Le NJ: MSF (MLL septin-like fusion), a fusion partner gene of MLL, in a therapy-related acute myeloid leukemia with a t(11;17)(q23;q25). Proc Natl Acad Sci USA. 1999, 96: 6428-6433. 10.1073/pnas.96.11.6428.CrossRefPubMedPubMedCentral
8.
Kalikin LM, Sims HL, Petty EM: Genomic and expression analyses of alternatively spliced transcripts of the MLL septin-like fusion gene (MSF) that map to a 17q25 region of loss in breast and ovarian tumors. Genomics. 2000, 63: 165-172. 10.1006/geno.1999.6077.CrossRefPubMed
9.
Russell SE, McIlhatton MA, Burrows JF, Donaghy PG, Chanduloy S, Petty EM, Kalikin LM, Church SW, McIlroy S, Harkin DP, Keilty GW, Cranston AN, Weissenbach J, Hickey I, Johnston PG: Isolation and mapping of a human septin gene to a region on chromosome 17q, commonly deleted in sporadic epithelial ovarian tumors. Cancer Res. 2000, 60: 4729-4734.PubMed
10.
Sandrock K, Bartsch I, Busse A, Busse E, Zieger B: Characterization of human septin interactions. Biol Chem. 2011, 392: 751-761. 10.1515/BC.2011.081.CrossRefPubMed
11.
Peterson EA, Kalikin LM, Steels JD, Estey MP, Trimble WS, Petty EM: Characterization of a SEPT9 interacting protein, SEPT14, a novel testis-specific septin. Mamm Genome. 2007, 18: 796-807. 10.1007/s00335-007-9065-x.CrossRefPubMed
12.
Gonzalez ME, Peterson EA, Privette LM, Loff reda-Wren JL, Kalikin LM, Petty EM: High SEPT9_v1 expression in human breast cancer cells is associated with oncogenic phenotypes. Cancer Res. 2007, 67: 8554-8564. 10.1158/0008-5472.CAN-07-1474.CrossRefPubMed
13.
Stanbery L, D'Silva NJ, Lee JS, Bradford CR, Carey TE, Prince ME, Wolf GT, Worden FP, Cordell KG, Petty EM: High SEPT9_v1 expression is associated with poor clinical outcomes in head and neck squamous cell carcinoma. Transl Oncol. 2010, 3: 239-245.CrossRefPubMedPubMedCentral
14.
Amir S, Wang R, Matzkin H, Simons JW, Mabjeesh NJ: MSF-A interacts with hypoxia-inducible factor-1alpha and augments hypoxia-inducible factor transcriptional activation to affect tumorigenicity and angiogenesis. Cancer Res. 2006, 66: 856-866. 10.1158/0008-5472.CAN-05-2738.CrossRefPubMed
15.
Bennett KL, Romigh T, Eng C: Disruption of transforming growth factorbeta signaling by five frequently methylated genes leads to head and neck squamous cell carcinoma pathogenesis. Cancer Res. 2009, 69: 9301-9305. 10.1158/0008-5472.CAN-09-3073.CrossRefPubMed
16.
Toth K, Galamb O, Spisak S, Wichmann B, Sipos F, Valcz G, Leiszter K, Molnar B, Tulassay Z: The influence of methylated septin 9 gene on RNA and protein level in colorectal cancer. Pathol Oncol Res. 2011, 17: 503-509. 10.1007/s12253-010-9338-7.CrossRefPubMed
17.
Hannibal MC, Ruzzo EK, Miller LR, Betz B, Buchan JG, Knutzen DM, Barnett K, Landsverk ML, Brice A, LeGuern E, Bedford HM, Worrall BB, Lovitt S, Appel SH, Andermann E, Bird TD, Chance PF: SEPT9 gene sequencing analysis reveals recurrent mutations in hereditary neuralgic amyotrophy. Neurology. 2009, 72: 1755-1759. 10.1212/WNL.0b013e3181a609e3.CrossRefPubMedPubMedCentral
18.
Amir S, Golan M, Mabjeesh NJ: Targeted knockdown of SEPT9_v1 inhibits tumor growth and angiogenesis of human prostate cancer cells concomitant with disruption of hypoxia-inducible factor-1 pathway. Mol Cancer Res. 2010, 8: 643-652. 10.1158/1541-7786.MCR-09-0497.CrossRefPubMed
19.
Gonzalez ME, Makarova O, Peterson EA, Privette LM, Petty EM: Up-regulation of SEPT9_v1 stabilizes c-Jun-N-terminal kinase and contributes to its pro-proliferative activity in mammary epithelial cells. Cell Signal. 2009, 21: 477-487. 10.1016/j.cellsig.2008.11.007.CrossRefPubMed
20.
Surka MC, Tsang CW, Trimble WS: The mammalian septin MSF localizes with microtubules and is required for completion of cytokinesis. Mol Biol Cell. 2002, 13: 3532-3545. 10.1091/mbc.E02-01-0042.CrossRefPubMedPubMedCentral
21.
Estey MP, Di Ciano-Oliveira C, Froese CD, Bejide MT, Trimble WS: Distinct roles of septins in cytokinesis: SEPT9 mediates midbody abscission. J Cell Biol. 2010, 191: 741-749. 10.1083/jcb.201006031.CrossRefPubMedPubMedCentral
22.
Peterson EA, Stanbery L, Li C, Kocak H, Makarova O, Petty EM: SEPT9_i1 and genomic instability: Mechanistic insights and relevance to tumorigenesis. Genes Chromosomes Cancer. 2011, 50: 940-949. 10.1002/gcc.20916.CrossRefPubMedPubMedCentral
23.
Montagna C, Lyu MS, Hunter K, Lukes L, Lowther W, Repert T, Hissong B, Weaver Z, Reid T: The Septin 9 (MSF) gene is ampliofied and overexdpressed in mouse mammary gland ademocarcinomas and human breast cancer cell lines. Cancer Res. 2003, 63: 2179-2187.PubMed
24.
deVos T, Tetzner R, Model F, Weiss G, Schuster M, Distler J, Steiger KV, Grützmann R, Pilarsky C, Habermann JK, Fleshner PR, Oubre BM, Day R, Sledziewski AZ, Lofton-Day C: Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem. 2009, 55: 1337-1346. 10.1373/clinchem.2008.115808.CrossRefPubMed
Metadata
Title
Steps solidifying a role for SEPT9 in breast cancer suggest that greater strides are needed
Authors
Laura Stanbery
Elizabeth M Petty
Publication date
01-02-2012
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2013
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr3056

Other articles of this Issue 1/2013

Breast Cancer Research 1/2013 Go to the issue

Research article

Trends in incidence and detection of advanced breast cancer at biennial screening mammography in The Netherlands: a population based study

Research article

Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells

Research article

Premenopausal serum androgens and breast cancer risk: a nested case-control study

Research article

PIK3CAmutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups

Review

The role and function of cadherins in the mammary gland

Research article

Use of glucocorticoids and risk of breast cancer: a Danish population-based case-control study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits